Works matching DE "TRASTUZUMAB"
Results: 2884
Incidence and risk factors of trastuzumab-induced cardiac dysfunction in a predominantly Hispanic South Texas population: a descriptive study.
- Published in:
- Cardio-Oncology, 2025, v. 11, n. 1, p. 1, doi. 10.1186/s40959-025-00319-4
- By:
- Publication type:
- Article
Presentation and management of female breast cancer in Egypt.
- Published in:
- Eastern Mediterranean Health Journal, 2022, v. 28, n. 10, p. 725, doi. 10.26719/emhj.22.076
- By:
- Publication type:
- Article
Breast cancer overview: Current treatments.
- Published in:
- Practice Nursing, 2009, v. 20, n. 6, p. 282, doi. 10.12968/pnur.2009.20.6.42553
- By:
- Publication type:
- Article
Breast cancer patients should not live without a HER-2/neu tissue result -- But how safe can they live with it?
- Published in:
- Wiener Klinische Wochenschrift, 2004, v. 116, n. 1/2, p. 3, doi. 10.1007/BF03040416
- By:
- Publication type:
- Article
Radiolabelled <sup>177</sup>Lu‐Bispidine‐Trastuzumab for Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancers.
- Published in:
- Chemistry - A European Journal, 2024, v. 30, n. 14, p. 1, doi. 10.1002/chem.202303805
- By:
- Publication type:
- Article
Chemoselective Methionine Labelling of Recombinant Trastuzumab Shows High In Vitro and In Vivo Tumour Targeting.
- Published in:
- Chemistry - A European Journal, 2023, v. 29, n. 11, p. 1, doi. 10.1002/chem.202202491
- By:
- Publication type:
- Article
A Traceless Site‐Specific Conjugation on Native Antibodies Enables Efficient One‐Step Payload Assembly.
- Published in:
- Angewandte Chemie, 2022, v. 134, n. 36, p. 1, doi. 10.1002/ange.202204132
- By:
- Publication type:
- Article
Ethynylation of Cysteine Residues: From Peptides to Proteins in Vitro and in Living Cells.
- Published in:
- Angewandte Chemie, 2020, v. 132, n. 27, p. 11054, doi. 10.1002/ange.202002626
- By:
- Publication type:
- Article
Transition of average drug‐to‐antibody ratio of trastuzumab deruxtecan in systemic circulation in monkeys using a hybrid affinity capture liquid chromatography‐tandem mass spectrometry.
- Published in:
- Biopharmaceutics & Drug Disposition, 2023, v. 44, n. 5, p. 380, doi. 10.1002/bdd.2371
- By:
- Publication type:
- Article
Detection of doxorubicin, cisplatin and therapeutic antibodies in formalin-fixed paraffin-embedded human cancer cells.
- Published in:
- Histochemistry & Cell Biology, 2020, v. 153, n. 5, p. 367, doi. 10.1007/s00418-020-01857-x
- By:
- Publication type:
- Article
Pan-immune-inflammation Value in Metastatic HER2-Positive Breast Cancer Patients.
- Published in:
- Eurasian Journal of Medical Investigation, 2023, v. 7, n. 3, p. 209, doi. 10.14744/ejmi.2023.18471
- By:
- Publication type:
- Article
Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data.
- Published in:
- Eurasian Journal of Medical Investigation, 2023, v. 7, n. 2, p. 153, doi. 10.14744/ejmi.2023.22720
- By:
- Publication type:
- Article
Importance of Prognostic Nutritional Index in Patients with Metastatic Breast Cancer Treated with Trastuzumab Emtansine.
- Published in:
- Eurasian Journal of Medical Investigation, 2022, v. 6, n. 4, p. 484, doi. 10.14744/ejmi.2022.90000
- By:
- Publication type:
- Article
Effect of Inflammatory Markers on the Pathologic Complete Response in the Neoadjuvan Treatment of HER-2 Positive Local Advanced Breast Cancer.
- Published in:
- Eurasian Journal of Medical Investigation, 2022, v. 6, n. 4, p. 417, doi. 10.14744/ejmi.2022.65683
- By:
- Publication type:
- Article
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: Long-term survival analysis of the DESTINY-Breast03 trial.
- Published in:
- Breast Cancer Research Review, 2024, n. 45, p. 4
- By:
- Publication type:
- Article
Long-term outcomes of adjuvant trastuzumab for 9 weeks or 1 year for ERBB2-positive breast cancer: A secondary analysis of the SOLD randomized clinical trial.
- Published in:
- Breast Cancer Research Review, 2024, n. 45, p. 4
- By:
- Publication type:
- Article
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases.
- Published in:
- Breast Cancer Research Review, 2023, n. 40, p. 5
- By:
- Publication type:
- Article
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA).
- Published in:
- Breast Cancer Research Review, 2023, n. 40, p. 4
- By:
- Publication type:
- Article
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03.
- Published in:
- Breast Cancer Research Review, 2023, n. 40, p. 4
- By:
- Publication type:
- Article
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.
- Published in:
- Breast Cancer Research Review, 2022, n. 38, p. 5
- By:
- Publication type:
- Article
Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer.
- Published in:
- Breast Cancer Research Review, 2022, n. 37, p. 4
- By:
- Publication type:
- Article
Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial.
- Published in:
- Breast Cancer Research Review, 2021, n. 34, p. 5
- By:
- Publication type:
- Article
In Silico Design and Evaluation of scFv-CdtB as a Novel Immunotoxin for Breast Cancer Treatment.
- Published in:
- International Journal of Cancer Management, 2020, v. 13, n. 1, p. 1, doi. 10.5812/ijcm.96094
- By:
- Publication type:
- Article
In Silico Evaluation of Two Targeted Chimeric Proteins Based on Bacterial Toxins for Breast Cancer Therapy.
- Published in:
- International Journal of Cancer Management, 2019, v. 12, n. 2, p. 1, doi. 10.5812/ijcm.83315
- By:
- Publication type:
- Article
Immunogenicity of Rituximab, Trastuzumab, and Bevacizumab Monoclonal Antibodies in Patients with Malignant Diseases.
- Published in:
- International Journal of Cancer Management, 2018, v. 11, n. 11, p. 1, doi. 10.5812/ijcm.64983
- By:
- Publication type:
- Article
The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2015, v. 107, n. 8, p. 1, doi. 10.1093/jnci/djv136
- By:
- Publication type:
- Article
Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2015, v. 107, n. 8, p. 1, doi. 10.1093/jnci/djv136
- By:
- Publication type:
- Article
Effect of p95HER2/611CTF on the Response toTrastuzumab and Chemotherapy.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 11, p. 1, doi. 10.1093/jnci/dju291
- By:
- Publication type:
- Article
Comparative Effectiveness of Neoadjuvant Therapy for HER2–Positive Breast Cancer: A Network Meta-Analysis.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 9, p. 1, doi. 10.1093/jnci/dju203
- By:
- Publication type:
- Article
Making Sense of Dual HER2-Targeting in Early Breast Cancer?
- Published in:
- 2014
- By:
- Publication type:
- Editorial
Therapeutic Targeting of Integrin αvβ6 in Breast Cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2014, v. 106, n. 8, p. 1, doi. 10.1093/jnci/dju169
- By:
- Publication type:
- Article
Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2013, v. 105, n. 23, p. 1782, doi. 10.1093/jnci/djt321
- By:
- Publication type:
- Article
Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2013, v. 105, n. 13, p. 960, doi. 10.1093/jnci/djt121
- By:
- Publication type:
- Article
Cardiotoxicity Debated for Anthracyclines and Trastuzumab in Breast Cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2013, v. 105, n. 12, p. 835, doi. 10.1093/jnci/djt161
- By:
- Publication type:
- Article
HER2-Directed T-Cell Receptor–Mimicking Antibody: A “Me Too” or an Example of Novel Antitumor Aggressive Mimicry?
- Published in:
- JNCI: Journal of the National Cancer Institute, 2013, v. 105, n. 3, p. 161, doi. 10.1093/jnci/djs636
- By:
- Publication type:
- Article
Antitumor Activity of a Monoclonal Antibody Targeting Major Histocompatibility Complex Class I–Her2 Peptide Complexes.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2013, v. 105, n. 3, p. 202, doi. 10.1093/jnci/djs521
- By:
- Publication type:
- Article
PDQ (Physician Data Query).
- Published in:
- JNCI: Journal of the National Cancer Institute, 2012, v. 104, n. 17, p. 1278, doi. 10.1093/jnci/djs390
- Publication type:
- Article
Risk of Heart Failure in Breast Cancer Patients After Anthracycline andTrastuzumabTreatment: A Retrospective Cohort Study.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2012, v. 104, n. 17, p. 1293, doi. 10.1093/jnci/djs317
- By:
- Publication type:
- Article
Trastuzumab and Congestive Heart Failure: What Can We Learn From Use in the Community?
- Published in:
- 2012
- By:
- Publication type:
- Editorial
Cancer Stem Cell Hypothesis and Trastuzumab in HER2-Negative Tumors.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2012, v. 104, n. 13, p. 968, doi. 10.1093/jnci/djs307
- By:
- Publication type:
- Article
Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2012, v. 104, n. 2, p. 159, doi. 10.1093/jnci/djr490
- By:
- Publication type:
- Article
Hints of Future Progress for HER-2 Breast Cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2011, v. 103, n. 7, p. 535, doi. 10.1093/jnci/djr122
- By:
- Publication type:
- Article
Gastric Cancer: Trastuzumab Trial Results Spur Search for Other Targets.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2009, v. 101, n. 19, p. 1306, doi. 10.1093/jnci/djp341
- By:
- Publication type:
- Article
Trastuzumab Before Breast Surgery? Large Trial Says Yes But Does Not Quell Debate.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2009, v. 101, n. 7, p. 448, doi. 10.1093/jnci/djp072
- By:
- Publication type:
- Article
Trial Offers Early Test Case for Personalized Medicine.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2009, v. 101, n. 3, p. 136, doi. 10.1093/jncI/djn506
- By:
- Publication type:
- Article
Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2008, v. 100, n. 15, p. 1092, doi. 10.1093/jnci/djn216
- By:
- Publication type:
- Article
Inconsistency of HER2 Test Raises Questions.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2007, v. 99, n. 14, p. 1064, doi. 10.1093/jnci/djm075
- By:
- Publication type:
- Article
Trastuzumab Faces Trials, Clinical and Otherwise.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2006, v. 98, n. 5, p. 296, doi. 10.1093/jnci/djj110
- By:
- Publication type:
- Article
Oh, Canada: Public Outcry Pushed Demand for Trastuzumab for Early-Stage Breast Cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2005, v. 97, n. 18, p. 1327, doi. 10.1093/jnci/dji327
- By:
- Publication type:
- Article